TABLE 1

Demographic, epidemiological and clinical characteristics of 428 culture-confirmed multidrug-resistant tuberculosis (MDR-TB) patients exposed to bedaquiline-containing regimens

Age years35 (27–44)
Male263/428 (61.5)
Body weight at admission kg56 (47–65)
Height cm169 (160–176)
Migrant45/428 (10.5)
Employed110/413 (26.6)
Prisoner23/413 (5.6)
Pregnant1/133 (0.8)
Thyroid disease12/413 (2.9)
Heart disease40/318 (12.6)
Pre-existing ECG abnormality13/318 (4.1)
Alcoholism132/363 (36.4)
Drug abuse75/413 (18.2)
Methadone use0/318 (0.0)
Diabetes26/413 (6.3)
HIV infection testing425/428 (99.3)
HIV-positive94/425 (22.1)
CD4 count at baseline cells·mm-3269 (168–470)
Nadir CD4+ cell count cells·mm-3222 (160–402)
Antiretroviral therapy exposure92/94 (97.9)
Prior anti-TB therapy334/428 (78.0)
Prior courses of treatment lasting >1 month n2 (1–2)
Prior TB treatment outcome
 Success68/263 (25.9)
 Cure41/263 (15.6)
 Completion27/263 (10.3)
 Default35/263 (13.3)
 Transfer out20/263 (7.6)
 Failure140/263 (53.2)
Pulmonary surgery55/423 (13.0)
Previous MDR-TB169/317 (53.3)
Pulmonary involvement426/428 (99.5)
Extrapulmonary involvement11/428 (2.6)
Radiology involvement
 Cavitary lesion81/331 (24.5)
 Bilateral pulmonary with cavitary lesions147/331 (44.4)
 Bilateral pulmonary56/331 (16.9)
 Noncavitary nonbilateral pulmonary47/331 (14.2)
Sputum smear positive305/423 (72.1)
Sputum culture positive421/428 (98.4)
Drug resistance
 Streptomycin185/196 (94.4)
 Ethambutol186/240 (77.5)
 Pyrazinamide145/206 (70.4)
 Fluoroquinolones267/414 (64.5)
 Amikacin131/295 (44.4)
 Capreomycin127/305 (41.6)
 Kanamycin179/302 (59.3)
 Ethionamide135/226 (59.7)
 Cycloserine20/163 (12.3)
 Para-aminosalicylic acid70/196 (35.7)
 Linezolid4/38 (10.5)
 Rifabutin32/35 (91.4)
XDR-TB195/428 (45.6)
MDR- or XDR-TB contacts105/411 (25.6)
Hospital stay days179 (92–280)
  • Data are presented as median (interquartile range) or n/N (%). XDR-TB: extensively drug-resistant tuberculosis.